Lymphoma - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Lymphoma - Pipeline Review, H1 2012', provides an overview of the Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. 'Lymphoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Lymphoma.
- A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lymphoma pipeline depth and focus of Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Lymphoma Overview
- Therapeutics Development
- An Overview of Pipeline Products for Lymphoma
- Lymphoma Therapeutics under Development by Companies
- Lymphoma Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Lymphoma Therapeutics - Products under Development by Companies
- Lymphoma Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Lymphoma Therapeutics Development
- Bristol-Myers Squibb Company
- Genzyme Corporation
- Johnson & Johnson
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- Abbott Laboratories
- Amgen Inc.
- Sanofi-Aventis
- AstraZeneca PLC
- Eli Lilly and Company
- GlaxoSmithKline plc
- Seattle Genetics, Inc.
- Genentech, Inc.
- Antigenics, Inc.
- MMR Information Systems, Inc.
- Biotec Pharmacon ASA
- MedImmune LLC
- Gilead Sciences, Inc.
- Daiichi Sankyo Company, Ltd
- Merck & Co., Inc.
- Immunovative Therapies, Ltd.
- PharmaTech International, Inc.
- Lymphoma - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- StemEx - Drug Profile
- RG7159 - Drug Profile
- Enzastaurin - Drug Profile
- MAbThera - Drug Profile
- MLN8237 - Drug Profile
- Adcetris - Drug Profile
- Adcetris - Drug Profile
- Arzerra - Drug Profile
- LBH589 - Drug Profile
- BiovaxID - Drug Profile
- Pixantrone - Drug Profile
- Velcade - Drug Profile
- Afinitor - Drug Profile
- AMG-761 - Drug Profile
- Marqibo - Drug Profile
- Forodesine - Drug Profile
- Clearazide - Drug Profile
- Folotyn - Drug Profile
- Folotyn - Drug Profile
- HuMax-CD4 - Drug Profile
- Velcade + Rituximab - Drug Profile
- CMC-544 - Drug Profile
- Inotuzumab Ozogamicin + Rituxan - Drug Profile
- Treanda + Rituxan - Drug Profile
- Revlimid - Drug Profile
- R05072759 + Bendamustine - Drug Profile
- Arzerra + Bendamustine - Drug Profile
- Ofatumumab + DHAP - Drug Profile
- Pixantrone + Rituximab - Drug Profile
- Avastin + R-CHOP - Drug Profile
- RG7159 + CHOP - Drug Profile
- RO5072759 + Bendamustine - Drug Profile
- VELCADE-R-CAP - Drug Profile
- FavId + Sargramostim + Rituximab - Drug Profile
- Rituxan + FavId + GM-CSF - Drug Profile
- Bendamustine - Drug Profile
- Revlimid + Rituxan - Drug Profile
- Biosimilar Rituximab - Drug Profile
- PBO-326 - Drug Profile
- RO5072759 + Chemotherapy - Drug Profile
- Lymphoma Therapeutics - Drug Profile Updates
- Lymphoma Therapeutics - Discontinued Products
- Lymphoma Therapeutics - Dormant Products
- Lymphoma - Product Development Milestones
- Featured News & Press Releases
- Jan 13, 2012: Seattle Genetics Updates ADCETRIS Prescribing Information
- Jan 13, 2012: Seattle Genetics Updates ADCETRIS Prescribing Information
- Jan 09, 2012: Micromet Signs Cooperative Research & Development Agreement With National Cancer Institute To Expand Development Of Blinatumomab
- Jan 03, 2012: FDA's Oncologic Drugs Advisory Committee To Review Resubmitted Pixantrone New Drug Application On February 9, 2012
- Dec 20, 2011: Biovest International Announces Publication Of BiovaxID Lymphoma Vaccine In Yale Journal Of Biology And Medicine
- Dec 19, 2011: Millennium Presents Phase II Trial Results Of MLN8237 At 53rd Annual Meeting Of American Society Of Hematology
- Dec 19, 2011: Millennium Presents Phase II Trial Results Of MLN8237 At 53rd Annual Meeting Of American Society Of Hematology
- Dec 19, 2011: Millennium Presents Biomarker Data From Phase III Study Of VELCADE At 53rd Annual Meeting Of American Society Of Hematology
- Dec 14, 2011: Premiere Cooperative Group In Adult Lymphoma Research Chooses REVLIMID For Study In Second Most Common Lymphoma Subtype
- Dec 13, 2011: Biovest Announces Phase II Clinical Trial Data Of BiovaxID At Annual Meeting Of American Society Of Hematology 2011
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Lymphoma, H1 2012
- Products under Development for Lymphoma - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Bristol-Myers Squibb Company, H1 2012
- Genzyme Corporation, H1 2012
- Johnson & Johnson, H1 2012
- Boehringer Ingelheim GmbH, H1 2012
- F. Hoffmann-La Roche Ltd., H1 2012
- Kyowa Hakko Kirin Co., Ltd., H1 2012
- Abbott Laboratories, H1 2012
- Amgen Inc., H1 2012
- Sanofi-Aventis, H1 2012
- AstraZeneca PLC, H1 2012
- Eli Lilly and Company, H1 2012
- GlaxoSmithKline plc, H1 2012
- Seattle Genetics, Inc., H1 2012
- Assessment by Molecule Type, H1 2012
- Lymphoma Therapeutics - Drug Profile Updates
- Lymphoma Therapeutics - Discontinued Products
- Lymphoma Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Lymphoma, H1 2012
- Products under Development for Lymphoma - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
